Diagnostic Performance of APRI and FIB-4 for Confirming Cirrhosis in Indonesian HIV/HCV Co-infected Patients

CURRENT STATUS: UNDER REVISION

BMC Infectious Diseases  □ BMC Series

Evy Yunihastuti
Faculty of Medicine Universitas Indonesia
ev y.yunihastuti@gmail.com
ORCID: https://orcid.org/0000-0001-6650-0559

Bramantya Wicaksana
Cipto Mangunkusumo Hospital

Adrian Wiraguna
Cipto Mangunkusumo Hospital

Ainum Jhariah Hidayah
Cipto Mangunkusumo Hospital

Fhadilla Amelia
Cipto Mangunkusumo Hospital

Veritea Natali
Cipto Mangunkusumo Hospital

Alvina Widhani
Universitas Prima Indonesia Fakultas Kedokteran

Andri Sanityoso Sulaiman
Faculty of Medicine Universitas Indonesia

Juferdy Kurniawan
Faculty of Medicine Universitas Indonesia

DOI:
10.21203/rs.2.20592/v1

SUBJECT AREAS
Infectious Diseases
KEYWORDS

APRI, FIB-4, transient elastography, HIV, HCV
Abstract

Background

After successful of antiretroviral therapy, highly effective direct acting antiviral (DAA) make HCV elimination reasonable in HIV/HCV co-infected patients. However, in achieving this target, there are still barriers to start DAA treatment, particularly in the area of liver fibrosis assessment that determine the duration of therapy. We aimed to assess the diagnostic performance of APRI and FIB-4 for diagnosing cirrhosis in HIV/HCV co-infected patients using hepatic transient elastography (TE) as gold standard.

Method

This is an retrospective study on HIV/HCV co-infected patients who concomitantly performed hepatic TE measurement, APRI, and FIB-4 evaluation before HCV treatment initiation at a tertiary hospital in Jakarta from 2014 to 2019. Sensitivity, specificity and diagnostic accuracy of indirect biomarkers for liver stiffness measurement (LSM) ≥ 12.5 kPa was determined by receiver operator characteristics curves.

Results

233 HIV/HCV co-infected patients on stable antiretroviral therapy were included, of whom 91.5% were male with mean age of 37 (SD 5) years. Only 28.7% of patients were classified as cirrhosis (F4). Using TE as gold standard (≥12.5 kPa), the low threshold of APRI (1) had specificity 95%, sensitivity 48.4%, correctly classified 81.6% of patients, with moderate performance, AUROC at 0.72 (95% CI 0.63-0.80). The optimal cut-off of FIB-4 was 1.66 [specificity 92.5%, sensitivity 53.1%, AUROC at 0.73 (95% CI 0.65-0.81)] and correctly classified 81.1% of the patients.

Conclusion

APRI score > 1 and FIB-4 score > 1.66 had moderate performance with high specificity in diagnosing cirrhosis. These biochemical markers could be used while TE is not available.

Background

Hepatitis C virus (HCV infection) is one of global health problem that can increase morbidity and...
mortality in HIV-infected population. In 2017, about 71 million people living with chronic HCV infection globally, of which only 19% (13.1 million) knew their diagnosis. The estimated prevalence in South-East Asia was 0.5% with incidence 14.8 (95% CI 12.5–26.9) per 100000 population in 2015.[1] In Indonesia, HCV infection prevalence is estimated at 1%, of which 90% comes from intravenous drug user.[2] World Health Organization (WHO) recently released targets for HCV elimination by 2030, targeting 80% HCV-infected patients being treated.[1] A large gap between HCV-diagnosed patients and HCV-treated patients still exist to achieve this global target since only around 10% of HCV-infected patients in South East Asia have been treated.[3] Achieving global elimination of HCV need major increase in service all populations along the entire cascade of care, including testing, linkage to care, retention in care, treatment, chronic care and prevention of primary infection and reinfection.[4] In 2017, Indonesian government started free direct acting antiviral (DAA) program for HCV, mainly sofosbuvir and daclatasvir combination.[5,6] This 12 weeks combination for non-cirrhotic patients and 24 weeks for cirrhotic-patients shown similar success rate for both HIV/HCV co-infected patients and HCV mono-infected patients.[7,8] Despite these facts, there are still many barriers to start HCV treatment, especially in defining liver fibrosis phase. Liver biopsy has been gold standard for liver fibrosis assessment for a long time. This invasive procedure carries some serious side effects and can only be done in specialized care. Transient elastography (TE) is a non-invasive method that measures liver stiffness using both ultrasound and low-frequency elastic waves to define liver fibrosis phase.[7] This method has been validated in viral hepatitis with equal performance in HCV and HIV/HCV co-infection.[8] However, it is not widely available in Indonesia and still carries a high-cost examination. Several laboratory tests, scores, and indices have been developed for non-invasive prediction of cirrhosis (F4) in HCV mono-infected patients. Aspartate aminotransferase (AST)-to- platelet ratio (APRI), fibrosis-4 (FIB4), modified APRI, Forns, and Göteborg University Cirrhosis Index (GUCI) are based on routine laboratory parameters and readily available in clinical practice. The two most common and validated used are APRI and FIB-4. WHO ranked these two scores as preferred non-invasive markers of fibrosis in resource-limited setting.[9] Since the determination of liver cirrhosis significantly influences the decision for treatment duration of
sofosbuvir and daclatasvir, optimal cut-off of APRI and FIB-4 to diagnose cirrhosis need to be defined in our HIV/HCV co-infected population.

Methods

Study Design

A retrospective study on HIV/HCV co-infected patients who concomitantly performed hepatic TE measurement, APRI, and FIB-4 evaluation before HCV treatment initiation at HIV Integrated Clinic, Cipto Mangunkusumo Hospital, Jakarta between 2014 and December 2019. We aimed to assess the diagnostic performance of APRI and FIB-4 for diagnosing liver cirrhosis in Indonesian HIV/HCV co-infected patients using hepatic TE (Fibroscan®) as a gold standard.

Eligibility Criteria

Inclusion criteria were infection with HCV defined as a positive HCV-RNA, HIV infection on stable antiretroviral treatment, and no prior HCV treatment. Exclusion criteria were hepatocellular carcinoma and invalid TE assessment.

Instrumental Assessment

Liver fibrosis or cirrhosis was assessed using transient elastography (FibroScan 502®, Echosens, France) by trained operators according to the manufacturer’s protocol. The procedures of liver stiffness measurement (LSM) were patient in a supine position, then M probe was put in intercostal spaces on the right lobe. The value of LSM was expressed in kilopascal (kPa). Patients were recommended to do fasting before the examination. LSM values were included in this analysis with at least 10 valid measures, over 70% success rate and interquartile range (IQR) less than 30% of the median value of LSM. The following cut-offs were used to stage the liver fibrosis are F0-F1<7.1 kPa, F2 (significant fibrosis) 7.1-9.4 kPa, F3 (advanced fibrosis) 9.5-12.4 kPa, and F4 (cirrhosis) ≥12.5 kPa. [8]

The APRI score was calculated using the formula: [(AST level/ULN)/platelet count (10^9/L)] × 100. The reference upper normal limit (ULN) for AST used in our hospital was 44 IU. While the FIB-4 score was using formula: age x AST/(platelet count x √ALT). The TE cut-off used to define cirrhosis was a minimum of 12.5 kPa.
**Statistical analysis**

All statistical analysis were performed using STATA statistical package for Windows version 12.0 (Statacorp, USA). The description of socio-demographics, HIV characteristics, and HCV characteristics was performed using standard descriptive methods. Categorical variables were expressed as raw numbers and percentages and compared using the chi-square test, and continuous variables were described by means and standard deviation (normal distribution) or median and IQR 25-75% (non-normal distribution assessed by Kolmogorov-Smirnov test). The proportion of liver cirrhosis (F≥4) was assessed as the number of patients with LSM of minimum 12.5 kPa and expressed with its 95% confidence interval. Test combinations were evaluated following a sequential approach to potentially establish an absence or presence of non-cirrhosis (F0-F3) and cirrhosis (F≥4). A two-sided p value <0.05 was considered to be statistically significant.

Performances of APRI and FIB-4 in diagnosing cirrhosis were evaluated from Area Under Receiver-Operator Curves (AUROCs), considering TE as the gold standard. Using WHO hepatitis C guidelines, two thresholds for fibrosis (F≥4) with APRI examined: 2 (high threshold) and 1 (low threshold).[8,10]

While the diagnosis of cirrhosis (F≥4) with FIB-4 was examined as 1.94 and 3.25 cut-offs based on previous study in HIV/HCV co-infected patients.(12,13) The others diagnostic performances for different test were analyzed separately and in combination according to sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio (LR-), and accuracy (Ac). In finding the novel diagnostic cut-offs for APRI and FIB-4 score in our population, the ROCs were generated by plotting the relationship of the true positivity (sensitivity) and the false positivity (1-specificity) at various cut-off points of each score. Considering sensitivity and specificity, the cut-off points were selected according to the maximum values of specificity and optimal sensitivity.

**Results**

**Patient characteristics**

Of 223 study patients, 91.5% were male with a mean age of 37 (SD 5) years. All patients were under stable antiretroviral therapy (ART) medication, mostly efavirenz (EFV)-based regimen (43%) or
nevirapine (NVP)-based regimen (42.2%). Median absolute CD4 cell count was 508 (IQR 306) cells/mm³ and the median duration of ART was 6.8 (IQR 4) years. Most of patients (93.3%) had history of intravenous drug use (IVDU) and 71.3% patients reported to have past alcohol consumption. Only 8 patients (3.6%) had all hepatitis B, hepatitis C, and HIV infections. All demographics and HIV characteristics were similar between cirrhotic and non-cirrhotic patients, except ART-regimen used (table 1). We did not find any decompensated cirrhosis among 64 cirrhotic patients within recruitment phase (the data was not shown).

**Hepatitis C and liver fibrosis evaluation**

In this study, mean HCV RNA viral load was 6.12 (SD 0.81) log₁₀ IU/mL, as seen in table 2. Median LSM for all the patients was 8.8 (IQR 7.3) kPa. Based on predetermined cut-offs for liver cirrhosis (≥12.5 kPa), 159 (71.3%) patients were classified as a non-cirrhotic group (F0-F3) and 64 (28.7%) as a cirrhotic group (F4). Cirrhotic patients had median LSM 20.1 (IQR 10.4) kPa, while in non-cirrhotic patients the median LSM was 7.8 (IQR 3.8) kPa. Patients with cirrhosis had lower platelet count, higher ALT and AST level compared to non-cirrhotic patients. There was no difference between cirrhotic and non-cirrhotic patients in term of their HCV RNA viral load, hemoglobin, and kidney function (eGFR). The median values of fibrosis indices were: 0.41 (IQR 0.52) for APRI and 0.88 (IQR 0.73) for FIB-4. Higher values of APRI and FIB-4 were observed in patients with LSM ≥ 12.5 kPa compared to patients with LSM <12.5 kPa: APRI 0.97 (IQR 1.25) vs 0.34 (IQR 0.33), p < 0.001 and FIB-4 0.16 (IQR 1.78) vs 0.81 (0.45), p < 0.001.

**Performance of APRI scores for the diagnosis of cirrhosis**

For the diagnosis of cirrhosis, an APRI value of 2 (high threshold) shown sensitivity 18.7%, specificity 98.1%, positive predictive value 80%, negative predictive value 75%, positive likelihood ratio 9.9 and negative likelihood ratio 0.8, with very poor performance [AUROC 0.58 (95% CI 0.50-0.67)] and 75.3% were correctly classified. APRI value of 1 (low threshold) correctly classified 81.6% of patients and had sensitivity 48.4%, specificity 95%, positive predictive value 79.5%, negative predictive value 82.1%, positive likelihood ratio 9.6 and negative likelihood ratio 0.5. This value had moderate performance
with an AUROC at 0.72 (95% CI 0.63-0.80) and revealed to be the optimal cut-off in defining cirrhosis in our patients.

**Performance of FIB-4 scores for the diagnosis of cirrhosis**

Using optimal cut-off of FIB-4 in previous studies, a value of 3.25 (high threshold) correctly classified 77.1% of patients with sensitivity 23.4%, specificity 98.7%, positive predictive value 88.2%, negative predictive value 76.2%, positive likelihood ratio 18.6 and negative likelihood ratio 0.8 in diagnosing liver cirrhosis. The performance was poor with an AUROC at 0.61 (95% CI 0.52-0.70). Lower FIB-4 cut-off 1.94 correctly classified 79.3% of patients with sensitivity 37.5%, specificity 96.2%, positive predictive value 80%, negative predictive value 79.2%, positive likelihood ratio 9.9, and negative likelihood ratio 0.6. The performance of FIB-4 cut-off 1.94 was also poor with an AUROC at 0.67 (95% CI 0.56-0.76). The optimal cut-off FIB-4 score for diagnosing cirrhosis in our patients was 1.66. At this cut-off, FIB-4 has sensitivity 53.1%, specificity 92.5%, positive predictive value 73.9%, negative predictive value 83.1%, positive likelihood ratio 7.0, and negative likelihood ratio 0.5. This FIB-4 new cut-off had better performance with AUROC at 0.73 (95% CI 0.65-0.81) and 81.1 % of patients were correctly classified.

**Discussion**

HIV-infected patient are about six times more likely to get HCV infection than HIV-negative counterparts (OR 5.8, 95% CI 4.5-7.4).[10] It is well known that HIV infected patient is less likely to spontaneously clear HCV infection.[12] In our previous regional study, 85.8% of HCV seropositive had detectable HCV RNA. This indicated that high proportion of HIV/HCV co-infected patients had chronic HCV infection.[13] In addition, HIV/HCV co-infected patients had higher HCV RNA and more rapid progression of end-stage liver disease despite their successful ART.[14] The new drugs DAA showed similar success rate in achieving sustained virological response (SVR), both in HIV co-infected or HCV mono-infected patient.[15]

To achieve elimination goal, there is an urgent need to limit the cost for diagnostic procedure before starting HCV therapy, especially in resource-limited setting. Previous report from Indonesia, an average cost before starting HCV therapy was USD 191, including USD 74 for TE examination.[2]
Simple and accurate liver fibrosis assessment other than TE examination that can be done in remote area is essential.[16,17] Two studies, both in Italy, had contradictory results. Mazzola, et al demonstrate the unreliability of APRI and FIB-4 for the assessment of cirrhosis while Merli, et al. conclude that these tests may be regularly used in HIV/HCV co-infected patients to exclude liver cirrhosis.[18,19] Therefore, we need to evaluate the performance of APRI and FIB-4 for diagnosing cirrhosis in our HIV/HCV co-infected population.

In our study, low threshold of APRI (1) demonstrate moderate performance [AUROC 0.72 (95% CI 0.63-0.80)]. This cut-off was lower than cut-off use in Mazzola, et al study (cut-off 2) with moderate performance (AUROC 0.77) but almost similar with Merli, et al study (cut off 0.97) with better performance [AUROC 0.84 (95% 0.81-0.880)]. One third of population in the Merli, et al study had cirrhosis as in our study, while prevalence of cirrhosis in Mazzola, et al study was 49.6%.[18,19] Low APRI threshold appeared to be better in diagnosis rather than detecting cirrhosis since the positive predictive value was good (79.5%), specificity was excellent (95%), and positive likelihood ratio was good (9.6). Using this threshold, 81.6% of the patients were correctly classified.

The optimal cut-off of FIB-4 in our population 1.66 was much lower than other studies. Merli, et al used FIB-4 cut-off 2.02 and Mazzola, et al used 5.88 for confirming cirrhosis.[18,19] Our new cut-off shown a moderate performance with AUROC 0.73 (95% CI 0.65-0.81). This new FIB-4 -cut-off was also better in diagnosis cirrhosis with the positive predictive value, specificity and positive likelihood ratio were good (73.9%, 92.5%, 7.0, respectively). Using this new cut-off, we accurately classified cirrhosis and non-cirrhosis 81.1% of our population.

In Indonesia only few TE machines are available, mainly located in big cities, and the cost is still high. Since the Indonesian government planned to expand free DAA program for HCV, the result our study could be implemented in many places, as WHO also recommends to use APRI and FIB-4 in resource-constraint countries.[2,19]

This study has several limitations. First, the number of end-stage liver diseases were small. This may be caused by the recruited patients came from outpatient clinic where we rarely found end-stage liver disease stage. Therefore, recruiting inpatient strongly recommended in the future study. Because of
this condition, we assuming statistical bias were occurred.[20] Quang Li, et al demonstrated similar limitation among chronic infection of hepatitis B virus (HBV), the sample proportion were inappropriate, merely 7.2% cirrhotic-patient were cirrhosis.[17] Second, we did not use liver biopsy as gold standard in defining liver cirrhosis. However, our study actually shown a real-world data of TE comparison with these indirect biochemical markers, especially in Asia. Although TE is good validated in HCV infected patients, TE result could be interfered by confounding factors such as hepatic inflammation or obesity. Moreover, we did not investigate performance of biochemical markers against liver biopsy.[20] Third, we need to carefully interpret this result in female patients, since men represent majority of the study population (91.5%), as observed in other studies.[19] Fourth, the use of cut off of APRI and FIB-4 from this study could only be applied among compensated cirrhosis patients. Perez-Latorre, et al mentioned decompensated cirrhosis patients have several activation of neurohormonal mechanism, leading to organ inflammatory damage, and decrease accuracy of TE.[21] Therefore, using TE in liver decompensated must be done carefully. Fifth, we assessed the diagnostic performances of biochemical markers of fibrosis using TE as a gold standard although we could not validate its performances against liver biopsy in our study population. We recommend further cohort study and larger sample to get new optimal and valid cut-off of APRI and FIB-4.

Conclusion
APRI and FIB-4 have moderate performance with high specificity in diagnosing cirrhosis. These biochemical markers could be used as diagnosis while TE is not available.

Abbreviations
Ac: accuracy; APRI: aspartate aminotransferase to platelet ratio index; ART: antiretroviral therapy; AUROC: area under receiver-operator curve; DAA: direct acting antiviral; FIB-4: fibrosis-4; GUCI: göteborg university cirrhosis index; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IVDU: intravenous drug user; LR-: negative likelihood ratio; LR+: positive likelihood ratio; LSM: liver stiffness measurement; NPV: negative predictive value; PPV: positive predictive value; Se: sensitivity; Sp: specificity; SVR: sustained virological response; TE: transient...
elastography; WHO: world health organization.

Declarations

**Ethics approval and consent to participate**

Ethical clearance was obtained from Ethical Committee of Faculty Medicine of University of Indonesia and local permission was acquired from Cipto Mangunkusumo hospital authority.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The data could be obtained by request to author’s email (evy.yunihastuti@gmail.com).

**Competing interests**

The authors declare no competing interests for this study.

**Funding**

The authors declare no fund received for this study.

**Authors’ contributions**

Conceptualization, EY, BM and AW; Data Curation, EY, BW and AW; Formal Analysis, AJH, BW and AW; Funding Acquisition, EY; Investigation, FA, AW, ASS, JK and VN; Methodology, EY; Project Administration, EY and VN; Resources, EY; Software, AJH; Supervision, EY, AW, ASS and JK; Validation, EY and AW; Visualization EY, AJH, BW and AW. Writing-Original Draft Preparation, EY, BW and AW; Writing-Review & Editing, EY, BW, AW, ASS and JK. All authors have reviewed and approved the submission of manuscript.

**Acknowledgements**

The authors would like to thank Indonesian government, Cipto Mangunkusumo hospital, research team and all patients who were participated in this study.

**References**

1. World Health Organization. Hepatitis C [Internet]. 2019. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c. Accessed 2019 Aug 15
2. Trickey A, Hiebert L, Perfect C, Thomas C, Luc J, Kaim E, et al. Hepatitis C virus elimination in Indonesia: epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning. Liver Int. 2019;00:1–12.

3. World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries, March 2018. Geneva: World Health Organization; 2018.

4. Lazarus J V, Peric JM, Picchio C, Dillon JF, Robinson M, Cernosa J, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Int Med. 2019;286:503–25.

5. Clinton health access initiative. Press release: CHAI announces partnership with governments in six low- and middle-income countries to initiate and expand hepatitis C treatment programs [Internet]. Available from: https://clintonhealthaccess.org/press-release-quick-start/. Accessed 2019 Nov 6.

6. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.

7. Sandrin L, Fourquet B, Hasquet J-M, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.

8. Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV-HCV coinfection: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(10):1684–93.

9. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis c infection. Geneva: World Health Organization; 2016.

10. Platt L, Easterbrook P, Gower E, Mcdonald B, Sabin K, Mcgowan C, et al. Prevalence
and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2015;16(7):797-808.

11. Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, et al. Progression of liver fibrosis in HIV/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy. PLoS One. 2015;10(9):1-18.

12. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55(Suppl 1):33-42.

13. Durier N, Yunihastuti E, Ruxrungtham K, Kinh N Van, Kamarulzaman A, Boettiger D, et al. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. J Viral Hepat. 2017;24(3):187-96.

14. Karageorgopoulos DE, Allen J, Bhagani S, Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol. 2015;7(15):1936-52.

15. Murdock RM, Brizzi MB, Perez O, Badowski ME. Public health considerations among people who inject drugs with HIV/HCV co-infection: a review. Infect Dis Ther. 2019;8(1):23-32.

16. Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, et al. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13(6):1-16.

17. Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT≤2 ULN A retrospective cohort study. Medicine (Baltimore). 2017;96(12):1-7.

18. Mazzola G, Adamoli L, Calvaruso V, Macaluso FS, Colletti P, Mazzola S, et al. Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients.
Infection. 2019;47(3):409–15.

19. Merli M, Galli L, Castagna A, Salpietro S, Gianotti N, Messina E, et al. Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients. New Microbiol. 2016;39(2):110-3.

20. Yen Y, Kuo F, Kee K, Chang K, Tsai M, Hu T, et al. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. 2018;1-16.

21. Pérez-Latorre L, Sánchez-Conde M, Rincón D, Miralles P, Aldámiz-Echevarría T, Carrero A, et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: Comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis. 2014;58(5):713–8.

Tables

Table 1. Description of the study population according to the liver cirrhosis status.

|                         | Total (n=223) | Non-cirrhosis (F0-F3) (n=159) | Cirrhosis (F4) (n=64) | p |
|-------------------------|--------------|-------------------------------|----------------------|---|
| Socio-demographic characteristics |              |                               |                      |   |
| Age, years, mean (SD)   | 37 (5)       | 37 (5)                        | 38 (6)               |   |
| Male, n(%)              | 204 (91.5)   | 142 (89.3)                    | 62 (96.8)            |   |
| BMI, kg/m², mean (SD)   | 22.55 (3.80) | 22.26 (3.56)                  | 23.27 (4.27)         |   |
| IVDU history, n(%)      | 208 (93.3)   | 148 (93.1)                    | 60 (93.7)            |   |
| Alcohol history, n(%)   | 159 (71.3)   | 114 (71.7)                    | 45 (70.3)            |   |
| HBsAg seropositivity, n(%) | 8 (3.6)     | 7 (4.4)                       | 1 (1.5)              |   |
| HIV characteristics      |              |                               |                      |   |
| ART duration, years, median (IQR) | 6.8 (4) | 6.8 (5)                       | 6.8 (2)              |   |
| Current CD4, cells/mm³, median (IQR) | 508 (306) | 508 (333)                    | 508 (215)            |   |
| ART used                |              |                               |                      |   |
| -2NRTI+EFV, n(%)         | 96 (43)      | 76 (47.7)                     | 20 (31.2)            |   |
| -2NRTI+NVP, n(%)         | 94 (42.2)    | 64 (40.2)                     | 30 (46.8)            |   |
| -2NRTI+LPV/r, n(%)       | 33 (14.8)    | 19 (11.9)                     | 14 (21.8)            |   |

SD: standard deviation; BMI: body mass index; IVDU: intravenous drug user; NRTI: nucleoside reverse transcriptase inhibitor; EFV: efavirenz; NVP: nevirapine; LPV/r: lopinavir/ritonavir

Table 2. Hepatitis C characteristics of the study population according to the liver cirrhosis status.
Table 3. Performances of APRI and FIB-4 in predicting cirrhosis using transient elastography as a gold standard.

|                  | Total (n=223) | Non-cirrhosis (F0-F3) n=159 | Cirrhosis (F4) n=64 |
|------------------|---------------|------------------------------|---------------------|
| **HCV-RNA, log_{10}, mean (SD)** | 6.12 (0.81) | 6.15 (0.84) | 6.06 (0.73) |
| **Hemoglobin, g/dL, mean (SD)** | 13.8 (2.3) | 13.9 (2.0) | 13.5 (2.8) |
| **Platelet, 10^3/mL, median (IQR)** | 225 (77) | 249 (78) | 173 (72) |
| **ALT, U/L, median (IQR)** | 55 (51) | 50 (41) | 66.5 (71) |
| **AST, U/L, median (IQR)** | 41 (41) | 37 (25) | 71 (64) |
| **eGFR (CKD-EPI), mL/min/1.73 m^2, mean (SD)** | 108.5 (21.3) | 108.5 (20.7) | 108.5 (23.0) |
| **LSM (kPa), median (IQR)** | 8.8 (7.3) | 7.8 (3.8) | 20.1 (10.4) |
| **APRI score, median (IQR)** | 0.41 (0.52) | 0.34 (0.33) | 0.97 (1.25) |
| **FIB-4 score, median (IQR)** | 0.88 (0.73) | 0.81 (0.45) | 1.69 (1.76) |

Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; LR-: negative likelihood ratio; LR+: positive likelihood ratio; Ac: accuracy; K: kappa; AUROC: area under the receiving operator curve.

HCV-RNA: Hepatitis C virus-ribonucleic acid; ALT: alanine aminotransferase; AST: aspartate aminotransferase; eGFR: estimated glomerular filtration rate; CKD-EPI: chronic kidney disease-epidemiology collaboration; LSM: liver stiffness measurement; APRI: AST to platelet ratio index; FIB-4: the fibrosis-4 index; IQR: interquartile range; SD: standard deviation; kPa: kilo pascal.